Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1

Jing Zou1*, Ling Liu1*, Qi Wang1, Fuqiang Yin2, Zhijun Yang1, Wei Zhang1, Li Li1

1Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University; Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor Ministry of Education Key Laboratory, Nanning 530021, Guangxi, P. R. China; 2Medical Scientific Research Centre, Guangxi Medical University, Nanning 530021, Guangxi, P. R. China. *Equal contributors.

Received January 19, 2016; Accepted January 30, 2017; Epub March 15, 2017; Published March 30, 2017

Abstract: Drug resistance is an obstacle to the treatment of epithelial ovarian cancer. Recently, research has suggested that miRNAs (microRNAs) are involved in cancer development, and speculation has been made about their possible involvement in drug resistance. Thus, we attempted to identify selected miRNAs involved in the development of chemo-resistance in epithelial ovarian cancer. Using miRNA profiles of a panel of cisplatin-resistant (SKOV3/DDP) cells, we validated data using quantitative real time-PCR (QRT-PCR), and studied the effects of miR-429 on cancer cell chemo-sensitivity, using gain- and loss-of-function studies. Data show that SKOV3/DDP expressed less miR-429 compared with parental SKOV3 cells and lower miR-429 expression conferred shorter overall survival (OS) and less progression-free survival (PFS) than the patients with more miR-429 expression (P < 0.01). Upregulation of miR-429 increases cisplatin sensitivity in epithelial ovarian cancer cells. Studies have confirmed that the zinc finger E-box binding homeobox1 (ZEB1) is a direct and functional target of miR-429 and that over-expression of miR-429 reduces autophagy-related protein anti-ATG7, anti-LC3A/B (P < 0.05). Thus, overexpression of miR-429 may suppress ZEB1, and may be a potential sensitizer to cisplatin treatment that may have therapeutic implications.

Keywords: Epithelial ovarian cancer miR-429 cisplatin resistance ZEB1

Introduction

Epithelial ovarian cancer (EOC) has the highest mortality worldwide and is the fourth most common cause of death due to cancer among women [1]. Early-stage malignancy is frequently asymptomatic and difficult to detect; thus, by the time of diagnosis, most women have advanced disease [2]. EOC is most frequently treated with platinum- and taxane-based chemotherapy. Although initially, 80-90% of patients will have a complete clinical response to this treatment [3], most of these women will then develop platinum-resistance to a wide range of chemotherapeutic agents and develop recurrent or persistent disease [4]. Thus, the 5-year overall survival (OS) of patients with advanced-stage epithelial ovarian cancer (EOC) is only 30% [5, 6]. A significant impediment to improving response rates and subsequent patient outcomes is an incomplete understanding of the molecular underpinnings of EOC cell chemo-sensitivity.

MiRNAs (microRNAs) are a class of small, non-coding RNAs, about 19 to 25-nucleotides in length that regulate the expression of thousands of genes by either translation suppression or degradation of mRNA [7-9]. MiRNAs are known to play important roles in most physiological processes-normal development, cell growth, differentiation, and apoptosis in mammals [10]. Until now, 1,048 human miRNAs have been annotated in miRNA registries (miRBase, www.mirBase.org) and this number is increasing [11]. Several studies have focused on circulating miRNAs in the blood as a means of non-invasive diagnosis and early detection in EOC [12]. MiRNAs regulate cancer cell biology, including multiple drug resistances by binding
MiR-429 associated with drug resistance in ovarian cancer

to imperfect complementary sites in the 3'-untranslated region of their target mRNA transcripts [13-15], leading to the development of microRNAs as early indicators of disease and to their potential therapeutic use. An appreciation of the effects of these repressors may provide a more complete understanding of the indirect effects of miRNA dysregulation in diseases such as cancer, and to their successful clinical application. Hence, miRNA expression analysis has a diagnostic value and is a promising therapeutic approach.

MiR-429 belong to the miR-200 family, which consists of five members localized in two genomic clusters (miR-200b/a, miR-429 on chromosome 1, and miR-200c, miR-141 on chromosome 12) [16]. The miR-200b/c/429 cluster may contribute to the development of MDR in both gastric and lung cancer cell lines, at least in part by modulation of apoptosis via targeting BCL2 and XIAP [17]. Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200s and zinc finger E-box binding homeobox1 (ZEB1) [18]. Therefore, our goal was to determine the role of miR-429 in EOC.

Material and methods

Patients and samples

Surgical specimens from 72 EOC patients were obtained postoperatively from 2007 to 2011 from the Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University. The study was endorsed by the Ethics Committee of the Guangxi Medical University. All patients gave signed, informed consent for their tissues to be used for scientific research. Ethical approval for the study was obtained from the local institutional review board. Tissues were obtained and stored at -80°C prior to qRT-PCR assay. The accuracy of drug resistance prediction was evaluated by receiver-operating characteristics (ROC) curves (AUC).

Cell lines and cell culture

The human EOC cell line SKOV3 was stored in our laboratory, and routinely maintained in DMEM (Corning, city, state) supplemented with 10% fetal bovine serum (FBS) (Corning) and 2 μM/L L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO₂. A stable cisplatin-resistant cell line (SKOV3/DDP) was established from SKOV3 cells as previously described [19, 20].

cDNA synthesis and quantitative real-time-PCR to detect miR-429

Total RNA was prepared from cells using an RNeasy® Mini Kit (QIAGEN, Germany) according to the manufacturer’s instructions. RNA integrity was verified using a NanoDrop2000 (1.8-2.0; NanoDrop2000, Thermo, city, state). RNA (1 μg) was reverse transcribed using a miScript II RT (Qiagen, Germany) as detailed in the manufacturer’s instructions. A quantitative real-time PCR (qRT-PCR) assay, used to measure miR-429 in RNA extracted from EOC cell lines and ovarian tumors, was performed with FastStart Universal SYBR Green PCR Master (ROX) in a total volume of 10 μL on an MxPro 3000p (Agilent, Palo Alto, USA). The conditions were as follows: 40 cycles of three-step PCR (95°C for 15 sec, 55°C for 30 sec and 72°C for 30 sec) following initial denaturation at 95°C for 10 min. All primers were supplied by BGI (The Beijing Genomics Institute). Primer sequences were as follows: 5’-CGTAATACTGT-CTGGTAAAACCGT-3’ for miR-429; 5’-CAAGGATGACACGCAATTCG-3’ for U6; U6 was used as internal standards to normalize the expression of miR-429.

Cell viability assay and cell growth assay

Proliferation assay: Cell proliferation assays were performed using a Cell Counting Kit-8 (CCK8). Cells were seeded at a density of 1.0 × 10⁵ cells per well in 96-well plates, and were incubated at 37°C for 1, 2, 3, and 4 days, with fresh media containing either drug and/or vehicle being replaced every day where appropriate.

IC50 assay: Cell viability and IC50 were measured with a Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan). Cells were seeded in 96-well plates 12 h before treatment at a density of 5,000 cells/well. Cells were treated with increasing concentrations of cisplatin (5, 10, 20, and 40 μM up to 80 μM) dissolved in 100 μL DMEM. DMEM (100 μL) without cisplatin was added to the cells as a negative control and 48 h of incubation, DMEM
was changed with RPMI-1640 for 100 μl/well. RPMI-1640 (100 μL) without cells was used as a blank control. CCK8 (10 μL) was added and incubated for an additional 2 h. The absorbance at 450 nm was read using a microplate MULTISKAN GO (Thermo, city, state). 

\[ Invitro \] cytotoxicity was measured using percent cell survival expressed as \[
\left( \frac{\text{OD}_{\text{control}} - \text{OD}_{\text{blank}}}{\text{OD}_{\text{treated}} - \text{OD}_{\text{blank}}} \right) \times 100
\]
All experiments were repeated in triplicate and mean values reported.

**Lentiviral infection**

Lentivirus packaging containing an miR-429 expression plasmid and its negative control (NC), LV-3 (pGLVH1/GFP+Puro), followed by a green fluorescent protein (GFP) reporter were designed and synthesized by GenePharma Inc (Shanghai, China). The resultant lentivirus containing the miR-429 (LV3-miR-429) and the NC sequences (LV3-NC), were used to infect SK/DDP cells to establish stably overexpressed cell lines. Lentivirus was added to 1.5 × 10^5 SK/DDP cells (final titration of 10^9) for 24 h, and then replaced with fresh DMEM with 10% FBS. GFP expression in infected cells (SK/DDP+miR-429 or SK/DDP-NC) was measured using fluorescent microscopy and more than 85% of cells were found to express GFP 72 h later. After Puro selection, stable pool cells were obtained, and miR-429 expression was confirmed by qRT-PCR.

A microOFF™ miR-429 inhibitor (Ribobio, Guangzhou, China) was transfected using Lipofectamine 2000 transfection agent (Invitrogen) according to the manufacturer’s instructions (final concentration 150 nM). Cells were incubated for 6 h in this reduced serum environment to optimize transfection, washed with PBS, and then incubated at 37°C at 5% CO₂ for 48 h. All samples were washed in PBS and resuspended in 100 μl binding buffer. Next, 5 μl Annexin V-PE and 5 μl 7-AAD were added and the cell suspension was incubated in a dark chamber at room temperature for 15 min. Apoptosis was measured using a FACS Calibur flow cytometer (BD Biosciences, city, state) and data were analyzed using Cell Quest software (BD Biosciences).

**MicroRNA target prediction**

Target sites for animal miRNAs are not evenly distributed within 3'UTR but rather grouped at both ends of 3'UTR [21]. The miRNA sequence was analyzed using miRBase (http://microrna.san ger.ac.uk/sequences/), and the target gene information of miR-429 were selected from the intersection of the target prediction results by Targetscan (http://www.targetscan.org/) [22], miRBase (http://www.mirbase.org/) [11], miRanda (http://www.microrna.org/microrna/home.do) [23], PicTar (http://pictar.mdc-berlin.de/) [24], miRecords (http://miRecords.um.niu.edu/miRecords.) [25].

**Western blot analysis**

Cells were washed twice with cold PBS and lysed in RIPA lysis buffer (Beyotime Inst Biotech, China) supplemented with protease inhibitors (2 μg/ml PMSF) for 30 min on ice. Cell lysates were then clarified by centrifugation (14,000 rpm) at 4°C for 30 min, and the supernatant was collected for experiments. Protein concentration of lysates was measured with a BCA Protein Assay Kit (Thermo Fisher Scientific, city, state). A total of 80 μg protein lysate was separated by 10% SDS-PAGE, and proteins were transferred onto PVDF membranes and blocked with blocking solution (5% skim milk in PBST). Membranes were incubated overnight with the primary antibody: rabbit anti-human ZEB1 (diluted 1:250, Cell Signaling Technology, city, state) and rabbit anti-human GAPHD (diluted 1:1000, Cell Signaling Technology, city,
MiR-429 associated with drug resistance in ovarian cancer

state) followed by the incubation with appropriate HRP-conjugated secondary antibody (diluted 1:1000, DAKO, Denmark). Western blot densitometry results were obtained with ImageJ software [26]. We also measured autophagy protein using an autophagy sampler kit (4445S, Cell Signaling Technology, city, state).

Luciferase assay

The ZEB1 3' UTR containing putative binding sites for miR-429 were cloned into pmirGLO vector (Promega, city, state), which was based on Promega dual-luciferase technology, with firefly luciferase (luc2) as the primary reporter gene and Renilla luciferase (hRluc-neo) as a control reporter gene. Two binding site in the 3'UTR of ZEB1 and its mutated version were cloned into luciferase reporter plasmids. MiR-429 mimics (40 pM, GenePharma Co, Ltd, Shanghai, China) and the reporter plasmids were co-transfected into HEK293 cells. Cells were harvested 24 h post-transfection and luciferase activities were assayed with Dual-Luciferase Reporter Assay System (Promega, E1960) according to the manufacturer's instructions. Then the ratio of luc2 activity to hRluc-neo activity in the miR-429 treated group was calculated and compared with ratios in the miR-NC group, which was arbitrarily defined as 100%. Each experiment was performed in triplicate.

Statistical analysis

All experiments were repeated at least three times and the data are expressed as the means ± standard deviation. Statistical analysis was conducted with SPSS 16.0 statistical analysis package. Differences between two groups of miR-429 were analyzed by two tailed student's t-test, and three groups were by One-way ANOVA; the value of miR-429 for the diagnosis chemo-resistant of EOC was analyzed by the ROC analysis; the survival curves were plotted by the Kaplan-Meier method, to construct a model for the prediction of survival, univariate and multivariate Cox regression model was performed. P < 0.05 was considered to indicate a statistically significant difference.

Results

Expression of miR-429 is associated with development cisplatin resistance

To explore the role of miR-429 involved in cisplatin resistance, total RNA was extracted from SKOV3 and SKOV3/DDP cells and qRT-PCR revealed that miR-429 was significantly down-regulated in SKOV3/DDP cells compared with parental SKOV3 cells (Figure 1A), data that are consistent with previous publications [27]. We measured cisplatin sensitivity in SKOV3/DDP cells exposed to various concentrations of cisplatin for 48 h. IC_{50} for cisplatin in SKOV3/DDP cells was 2.5-fold greater than parental SKOV3 cells (Figure 1B). Next, after manipulating miR-429 expression in SKOV3/DDP and SKOV3 cells using LV3-miR-429 and miR-429 inhibitors, respectively, we measured changes in drug sensitivity. As shown in Figure 1D, miR-429 was increased significantly in cells transfected with LV3-miR-429 compared with negative controls (LV3-miR-NC), and lowered IC_{50} values for cisplatin compared with the NC (Figure 1E). Conversely, the miR-429 inhibitor increased IC_{50} values for cisplatin in SKOV3 cells compared with miR-NC (Figure 1F). Thus, downregulation of miR-429 is implicated in the development of cisplatin resistance in SKOV3/DDP cells, and its over-expression can increase drug sensitivity.

Over-expression of miR-429 increased cisplatin sensitivity by inhibiting proliferation, inducing apoptosis and reducing autophagy of SKOV3/DDP cells

MiR-429-induced changes in OC cell viability were measured and miR-429 reduced both proliferation and colony-forming ability of SKOV3/DDP cells. A cell survival assay showed that LV3-miR-429 significantly inhibited cell growth compared with controls at 48 h (Figure 2A; P < 0.05). Colony formation assays confirmed that miR-429 inhibited cell growth. Colony formation was reduced in SKOV3/DDP cells transfected with miR-429 compared with the miR-NC in the presence of all concentrations of cisplatin (Figure 2B, 2C). Thus, miR-429 inhibits SKOV3/DDP cell growth.

Many chemotherapeutic agents exert anticancer activity by inducing apoptosis. Therefore, we studied the role of miR-429 in cisplatin-induced apoptosis. SKOV3/DDP cells were transfected with miR-429, control after cisplatin treatment for 48 h. Cells were stained and flow cytometry analysis indicated that apoptosis was greater in the miR-429 group compared to controls (Figure 2D, 2E).
MiR-429 associated with drug resistance in ovarian cancer

Previous studies indicate that autophagy is associated with tumor drug resistance and OC drug resistance [28]. Therefore, we measured miR-429 overexpression and found that miR-429 over-expression reduced Anti-ATG7 and Anti-LC3A/B (Figure 2F).

Figure 1. The expression of miR-429 in ovarian cancer cell lines. A. MiR-429 expression was measured by QRT-PCR in parental SKOV3 cells compared with that in cisplatin-resistant SKOV3/DDP cells. B. SKOV3/DDP and SKOV3 cells were treated with various concentrations of cisplatin for 48 h, and the 50% inhibitory concentration (IC_{50}) of cisplatin was measured by the CCK8 assay. C. ZEB1 expression was up-regulated in SKOV3/DDP cells compared with in the parental A2780 cells. D. Displayed that the expressions of miR-429 were significantly increased in SKOV3/DDP cells infected by LV3-miR-429 compared to the blank groups. E. SKOV3/DDP cells were transfected with LV3-miR-429 or LV3-miR-NC and were exposed to a range of cisplatin concentrations. The IC_{50} of cisplatin was shown. F. SKOV3 cells were transient transfected with miR-429 inhibitor or miR-NC and were exposed to a range of cisplatin concentrations. The IC_{50} of cisplatin was shown (*P < 0.05,**P < 0.01).

MiR-429 promoted SKOV3/DDP cell sensitivity to cisplatin via directly targeting ZEB1

As shown in Figure 1C, ZEB1 expression was high in the SKOV3/DDP cell line, but low in the parental SKOV3 cell line. The bioinformatics
MiR-429 associated with drug resistance in ovarian cancer

algorithm predicted that ZEB1 was a potential target gene of miR-429 (Figure 3A). Using the Expression Omnibus database (GEO), we found a microarray analyses (GSE56967) in HEY OC

Figure 2. miR-429 overexpression increased cisplatin sensitivity by inhibiting cell growth and promoting apoptosis. A. CCK8 assay data for SKOV3/DDP cells transfected with LV3-miR-429 or miR-NC. B. Colony formation data for SKOV3/DDP cells transfected with LV3-miR-429 or miR-NC, and then treated with cisplatin for 11-14 days. D, E. Apoptosis of SKOV3/DDP cells transfected with LV3-miR-429 or miR-NC and treated with cisplatin for 48 h. F. Protein after LV3-miR-429 transfection of SKOV3/DDP cells. *P < 0.05
MiR-429 associated with drug resistance in ovarian cancer

Figure 3. ZEB1 targeted by miR-429. A. ZEB1 was predicted to be a potential target of miR-429 and mutated sites of miR-429 are shown. B. Expression of ZEB1 in the microarray dataset GSE56967. C. ZEB1 protein after LV3-miR-429 transfection in SKOV3/DDP cells. D. ZEB1 protein after miR-429 inhibitor transfection in SKOV3 cells. E. Luciferase assay. HEK293T cells co-transfected with pmirGLO-ZEB1-wt or pmirGLO-ZEB1-mut and miR-429 mimics or NC. Relative luciferase activity. All data are shown as means ± sd of three separate experiments. **P < 0.01.

cells that were transiently transfected either with miR-429 oligos or negative control. High miR-429 significantly inhibited ZEB1 expression (~1.8-fold) compared with controls (Figure 3B). Western blots indicated ZEB1 expression was inhibited by miR-429 as ZEB1 protein was significantly reduced after transfection with LV3-miR-429 compared with controls in SKOV3/DDP cells (Figure 3C). In contrast, transfection of SKOV3 cells with miR-429 inhibitor ZEB1 compared with controls (Figure 3D).

We investigated whether ZEB1 is a direct target of miR-429 by studying the interaction between miR-429 and the 3’UTR of ZEB1 using a luciferase assay in HEK293T cells. Compared to negative control, cells co-transfected miR-429 suppressed luciferase gene expression, which was located upstream of the wild type 3’UTR of ZEB1. Mutation of both predicted recognition sites within the 3’UTR of ZEB1 abolished the inhibitory effect of miR-429. Thus, the inhibitory function of miR-429 on the target gene requires interaction with the predicted binding sites (Figure 3E).

Clinical significance of miR-429 expression in human OC tissues

To determine whether miR-429 expression was related to patient outcome, expression of miR-429 in cancer tissues from 72 EOC specimens were examined via qRT-PCR assay. miR-429 was down-regulated in chemo-resistant pati-
MiR-429 associated with drug resistance in ovarian cancer

Figure 4. Expression and prognostic value of miR-429 in epithelial OC tissues. (A) MiR-429 expression in cisplatin-sensitive (n = 40) and -resistant (n = 32) human EOC tissues. (B, C) Kaplan-Meier plots estimated according to miR-429 for overall survival (B) and PFS (C) of EOC patients.

Table 1. Correlation between miR-429 expression and clinicopathologic characteristics of 72 OC patients

<table>
<thead>
<tr>
<th>Factor</th>
<th>Cases</th>
<th>T value</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 50</td>
<td>38</td>
<td>-0.139</td>
<td>0.890</td>
</tr>
<tr>
<td>&gt; 50</td>
<td>34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIGO stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>14</td>
<td>0.165</td>
<td>0.869</td>
</tr>
<tr>
<td>III-IV</td>
<td>58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histological subtype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serous</td>
<td>40</td>
<td>0.391</td>
<td>0.697</td>
</tr>
<tr>
<td>Mucinous</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>60</td>
<td>-0.626</td>
<td>0.534</td>
</tr>
<tr>
<td>G2</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dead</td>
<td>34</td>
<td>-1.734</td>
<td>0.087</td>
</tr>
<tr>
<td>Survival</td>
<td>38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrence</td>
<td>59</td>
<td>-1.541</td>
<td>0.128</td>
</tr>
<tr>
<td>Unrecurrence</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Response to treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical remission</td>
<td>51</td>
<td>2.934</td>
<td>0.005</td>
</tr>
<tr>
<td>No clinical remission</td>
<td>21</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Sensitivity of miR-429 to identify the EOC with drug resistance

<table>
<thead>
<tr>
<th></th>
<th>AUC</th>
<th>95% CI</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Youden</th>
<th>Cutoff</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>MiR-429</td>
<td>0.744</td>
<td>0.63-0.86</td>
<td>0.633</td>
<td>0.714</td>
<td>0.348</td>
<td>0.532</td>
<td>P &lt; 0.05</td>
</tr>
</tbody>
</table>

Table 3) patients with less miR-429 expression had significantly shorter OS and PFS than those with high miR-429 expression (HR = 0.398, 95% CI = 0.201-0.709, P = 0.006 and HR = 0.491, 95% CI = 0.290-0.832, P = 0.041) (P < 0.01). Low miR-429-expressing patients had poorer prognoses [29]. Only the response to treatment was an independent prognostic factor for PFS or OS according to a multivariate Cox regression model (Table 3).

Discussion

EOC is the leading cause of death of all gynecologic malignancies, and the average 5-year survival is approximately 35-40%, but patients with advanced-stage disease have a survival rate of only 10-20% due to less effective chemotherapy, and drug resistance [4]. Cellular mechanisms of drug resistance are various [30] and microRNAs may be chief contributors to this resistance [31].

Recent studies suggest that during tumorigenesis, miRNAs can act either as oncogenic miRNAs (oncomiRs) or tumor suppressor miRNAs (tumor suppressor miRs) depending on the cellular context and the expression of the miRNA targets in the particular malignant tissues [32]. Therefore, miRNAs have been studied for associations with chemo-sensitivity [33]. For exam-
ple, upregulation of miR-21 reduced cell growth, proliferation and invasion via the JNK-1/c-Jun pathway [34]. Furthermore, miR-136 expression in human EOC can induce chemoresistance at least in part by downregulating apoptosis and promoting the repair of cisplatin-induced DNA damage [35].

Data from previous studies indicate that miR-429 is of the miR-200 family [36], and members of this family have been observed to be downregulated in several types of cancers and upregulated in others, so they may be correlated with chemo-resistance to paclitaxel and cisplatin in a panel of ovarian adenocarcinoma cell lines with inherent or acquired drug-resistance [36-38]. MiR-429 is reported to inhibit cell growth and invasion in colorectal carcinoma [39]. miR-200c expression may increase sensitivity to microtubule-targeting drugs by repressing the tubulin molecule TUBB3-high expression of which is linked with resistance against microtubule-directed agents [40].

Our results implicate miR-429 as a phenotypic regulator of chemo-resistance and our work is focused on the role of miR-429 as a regulator of chemotherapy response in EOC tumors. We found showed significantly lower miR-429 in cisplatin-resistant SKOV3/DDP cells compared with primary cultures of parent cells. Overexpression of miR-429 enhanced cisplatin chemosensitivity in SKOV3/DDP cells, but in SKOV3 cells, when transfected with miR-429 inhibitor, IC50 increased, data that are consistent with Wang’s study [41]. These findings suggest that miR-429 can regulate cisplatin chemosensitivity in SKOV3 cells and that miR-429 inhibited viability and proliferation of SKOV3/DDP cells compared with SKOV3/DDP and miR-NC groups.

Although many factors contribute to cisplatin-resistance of tumor cells, apoptosis has been shown to contribute to the development of drug resistance [42], and increased tumor cell autophagy after cisplatin treatment is key to this process [43]. MicroRNA-30a sensitizes tumor cells to cisplatin via suppressing Beclin 1-mediated autophagy [28]. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy [44]. Our data show that tumor cell apoptosis in the miR-429 group was higher (P < 0.05), data that are consistent with published work [45], and extra-neous expression of miR-429 significantly decreased autophagy related protein 7 (Atg-7) and LC3A/B expression, indicating that miR-429 expression may increase OC cell sensitivity to cisplatin by inducing apoptosis and inhibiting autophagy.

ZEB1, also known as TCF8 or delta EF1, is a transcriptional repressor of E-cadherin and polarity factor genes, and is a crucial EMT activator in human colon and breast cancers [46]. Epithelial to mesenchymal transition (EMT) is associated with overall OS or PFS, suggesting that tumor EMT is associated with chemo-resistance [47]. The miR-200 family is known as the main suppressor of EMT, which is a reversible embryonic program aberrantly activated in tumor progression and metastasis [48]. miR-429 is reported to regulate EMT-related marker genes by targeting Onecut2 in colorectal carcinoma [39]. Collectively, these data show that the miR-200 family is a powerful regulator of EMT/MET by targeting ZEB1 and ZEB2, which control E-cadherin expression. Indeed, inhibiting ZEB1 and ZEB2, ectopic expression of miR-

### Table 3. Cox proportional hazards regression analyses of clinical parameters and miR-429 signature in relation to disease outcomes

<table>
<thead>
<tr>
<th>Variable</th>
<th>Progress-free survival</th>
<th>Overall survival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Univariate analysis</td>
<td>Multivariate analysis</td>
</tr>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>p</td>
</tr>
<tr>
<td>Age</td>
<td>1.234 (0.732-2.079)</td>
<td>0.431</td>
</tr>
<tr>
<td>FIGO</td>
<td>1.717 (0.839-3.517)</td>
<td>0.139</td>
</tr>
<tr>
<td>Grade</td>
<td>0.872 (0.610-1.246)</td>
<td>0.451</td>
</tr>
<tr>
<td>Histological subtype</td>
<td>1.000 (0.727-1.376)</td>
<td>0.999</td>
</tr>
<tr>
<td>Residual lesions</td>
<td>1.661 (0.928-2.974)</td>
<td>0.088</td>
</tr>
<tr>
<td>Response to treatment</td>
<td>0.200 (0.111-0.358)</td>
<td>0.000</td>
</tr>
<tr>
<td>MiR-429</td>
<td>0.661 (0.475-0.915)</td>
<td>0.012</td>
</tr>
</tbody>
</table>
200s causes upregulation of E-cadherin and reduces cell motility [49]. Our data also show that endogenous ZEB1 expression was specifically downregulated by miR-429 at the post-transcriptional level, and was significantly elevated in SKOV3 cells after treatment with inhibitors of miR-429 as compared with controls. ZEB1 therefore may be a target of miR-429 and overexpression of miR-429 may decrease ZEB1 function. These findings provide new insights into the molecular functions of miR-429 as well as the role of ZEB1 in EOC chemotherapeutic resistance.

Previous work suggests that low miR-429 expression predicts poor PFS in advanced stage EOC patients [38]. We observed that, in 72 epithelial EOC samples miR-429 expression was decreased in drug-resistant samples, data that are similar to published reports [36]. Moreover, down-regulation of miR-429 was correlated with cisplatin resistance (P < 0.05), and poor prognosis for EOC patients, the same conclusion drawn for patients with osteosarcoma [26].

In summary, we demonstrated that miR-429 is deregulated in drug-resistant cell lines, targeting the expression of the resistant factor ZEB1. Furthermore, data suggest a possible role for miR-429 both as a prognostic factor and a marker of treatment failure in EOC. This discovery lays a foundation for new opportunities for EOC research and treatment.

Acknowledgements

This study was supported by a grant from the National Natural Science Foundation of China (No. 81572579) and Guangxi scientific research and technological development program topics (No. 14124004) and the Research Fund for the Doctoral Program of Higher Education of China (No. 20124503110003) Youth Science Foundation of Guangxi Medical University (No. GXMUYSF201402).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Li Li, Department of Gynecologic Oncology, Cancer Institute and Hospital, Guangxi Medical University, He Di Road 71, Nanning 530021, Guangxi, China. E-mail: liili@gxmu.edu.cn

References

MiR-429 associated with drug resistance in ovarian cancer


[38] Leskelä S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D and Rodriguez-Anton C. The miR-200 family controls beta-tubulin III expres-
MiR-429 associated with drug resistance in ovarian cancer


